Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

June 30, 2013

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

IGF-1

IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.

Trial Locations (1)

Cincinnati Children's Hospital Medical Center, Cincinnati